Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
BASI is in the medium-term up 171% in 2 years.
Description: Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. It operates in two segments, Contract Research Services and Research Products. The Contract Research Services segment offers various services, including product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; and stability testing to establish and confirm product purity, potency, and shelf life. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; and pharmacokinetic and safety testing services, as well as provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. The Research Products segment offers analytical produc
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.17||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-5.07%||Sales Growth - Q/Q||-2.04%||P/E||-9.35|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||31.27%||Operating Margin||-0.26%||Net Profit Margin||0.6%||Dividend Payout Ratio|
|Cash From Financing Activities||-750 K||Cash From Investing Activities||-230 K||Cash From Operating Activities||440 K||Gross Profit||1.8 M|
|Net Profit||150 K||Operating Profit||30 K||Total Assets||23.01 M||Total Current Assets||6.4 M|
|Total Current Liabilities||8.75 M||Total Debt||5.27 M||Total Liabilities||13.02 M||Total Revenue||5.73 M|
|High 52 week||2.1||Low 52 week||1.22||Last close||2.03||Last change||1.5%|
|RSI||56.25||Average true range||0.04||Beta||0.14||Volume||18.46 K|
|Simple moving average 20 days||1.6%||Simple moving average 50 days||2.35%||Simple moving average 200 days||18.49%|
|Performance Week||-0.49%||Performance Month||3.05%||Performance Quart||-0.98%||Performance Half||40.97%|
|Performance Year||23.91%||Performance Year-to-date||59.84%||Volatility daily||1.41%||Volatility weekly||3.15%|
|Volatility monthly||6.45%||Volatility yearly||22.36%||Relative Volume||145.56%||Average Volume||13.47 K|
|New High||New Low|
2020-05-14 08:33:10 | BASi Releases Earnings for Second Quarter of Fiscal 2020
2020-05-05 08:33:10 | Diane Tutko Francisco, Ph.D., Joins Inotiv to Lead Client Experience Team
2020-04-24 16:05:10 | BASi Announces Borrowing under Paycheck Protection Program
2020-04-22 12:21:14 | A Trio of Strong Performers to Consider
2020-02-14 08:33:10 | BASi Releases Earnings for First Quarter of Fiscal 2020
2020-02-12 09:18:10 | Inotiv Launches Website for Newly Unified Contract Research Services
2020-02-03 05:59:38 | How Much Are Bioanalytical Systems, Inc. NASDAQ:BASI Insiders Spending On Buying Shares?
2019-12-23 10:03:10 | BASi Closes Fiscal 2019 with Strong Fourth Quarter
2019-11-14 08:33:00 | BASi Launches Rebrand of its Contract Research Services Business Under the Name Inotiv
2019-09-29 09:07:09 | Does Bioanalytical Systems NASDAQ:BASI Have A Healthy Balance Sheet?
2019-08-15 12:38:29 | What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. NASDAQ:BASI?
2019-08-14 08:33:00 | BASi Continues Revenue Growth in Third Quarter of Fiscal 2019
2019-05-21 08:53:00 | Researchers Generate Better Data with BASi’s Redesigned Raturn™
2019-05-15 08:33:00 | BASi Continues Revenue Growth in Second Quarter of Fiscal 2019
2019-03-08 13:07:42 | Does Bioanalytical Systems, Inc. NASDAQ:BASI Have A Volatile Share Price?
2019-02-21 09:23:00 | BASi Appoints Joe Flynn as Chief Commercial Officer
2019-02-14 08:03:00 | BASi Reports Revenue Growth in First Quarter of Fiscal 2019
2018-12-20 08:03:00 | BASi Continues Revenue Gains to Close Fiscal 2018
2018-11-16 11:12:23 | Can Bioanalytical Systems Inc NASDAQ:BASI Improve Its Returns?
2018-11-01 08:43:00 | BASi Names John E. Sagartz Chief Strategy Officer
2018-10-17 08:33:00 | BASi Breaks Ground on Expansion of GLP Toxicology Facility in Indiana
2018-08-14 08:33:00 | BASi Reports Third Quarter Results with Revenue Gains
2018-07-09 09:00:00 | BASi Announces Appointment of John E. Sagartz to Board of Directors
2018-06-27 10:43:45 | Does Bioanalytical Systems Inc’s NASDAQ:BASI PE Ratio Signal A Buying Opportunity?
2018-05-25 16:57:18 | With An ROE Of 6.16%, Has Bioanalytical Systems Inc’s NASDAQ:BASI Management Done Well?
2018-05-15 08:33:00 | BASi Reports Second Quarter Results